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ABSTRACT
Background: Population-based data on distal cholangiocarcinoma (DCC) from the Western world are
not available, albeit essential to identify areas for improvement. This study investigated the incidence,
treatment and outcomes, including time trends and predictors for survival, in a nationwide cohort
of DCC.
Methods: This is a retrospective cohort study of patients diagnosed with DCC (2009–2016)
derived from the Netherlands Cancer Registry. Overall survival (OS) and its predictors were analyzed
using Kaplan–Meier and Cox regression analysis. Time trends (2009–2012 versus 2013–2016)
were assessed.
Results: Overall, 1338 patients with DCC were included, with 1-, 3- and 5-year OS of 46%, 18%, and
11%. Incidence of DCC was 0.55–0.90 per 100.000 per year. Median OS was 10.4 months across all
stages; 21.9 months for resected (n¼ 620, 46.3%), 6.7 months for unresected nonmetastatic (n¼ 445,
33.3%), and 3.6 months for metastatic DCC (n¼ 273, 20.4%) (p< .001). After resection, 30-day mortality
was 4.8% and 90-day mortality 7.7%. Patients with metastatic DCC who received chemotherapy
(n¼ 78, 28.6%) had a median OS of 8.2 versus 2.8 months for those not treated (p< .001). Over time,
resection rates (53.6% to 61.7%, p¼ .008) and use of palliative chemotherapy in metastatic DCC
(22.3% to 32.9%, p¼ .05) increased, without improvement in OS (10.3 vs 10.6 months, p¼ .55).
Independent poor prognostic factors for OS in resected disease were increasing age, pT3/T4 stage,
higher lymph node ratio, poor differentiation, and R1 resection.
Conclusions: In a nationwide cohort of DCC, resection rates and the use of chemotherapy increased
whereas OS remained stable at 10.4 months.
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Introduction
Distal cholangiocarcinoma (DCC) is an uncommon cancer,
accounting for 30–40% of all cholangiocarcinomas [1,2]. In
the resectable setting, upfront surgery is the treatment of
choice [3]. However, about half of all patients will suffer from
recurrence within 3 years, leading to a median overall sur-
vival (OS) of 33 months [4,5]. In the recent randomized multi-
center BILCAP trial, including patients with all subtypes of
biliary tract cancer, administration of adjuvant capecitabine
led to better outcomes in the per-protocol analysis when
compared to surgery alone [6]. In the unresectable setting,
palliative chemotherapy consisting of gemcitabine plus cis-
platin is the current standard of care. This was based on the
results of the ABC-02 trial which showed improved median
OS from 8.1 to 11.7 months when compared to gemcitabine
alone in patients with biliary tract cancer [7].
To better inform patients and identify areas for improve-
ment in the various stages of DCC, it is essential to study
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population-based outcomes. Current studies focus on
resected tumors and are often derived from high-volume,
non-Western centers [5]. The available all-stage cohorts typic-
ally combine DCC with other types of cholangiocarcinoma
[8,9]. To our best knowledge, no population-based all-
stage cohorts reporting outcomes for DCC only have
been published.
Therefore, we used population-based data to (1) describe
incidence, treatment and outcomes of all patients with DCC
in a nationwide registry, (2) analyze time trends, and (3)
determine independent prognostic factors for survival.
Material and methods
Data were derived from the Netherlands Cancer Registry
(NCR), which is a nationwide population-based registry
recording all newly diagnosed malignancies in the
Netherlands (about 17 million inhabitants). Patients are iden-
tified using the automated pathological archive (PALGA) and
the National Registry of Hospital Discharge Diagnosis.
Trained NCR registry administrators verify the diagnosis after
approximately nine months and add data from medical files
in all hospitals. This period ensures correct registration of
patients in whom the diagnosis has been revised. Registry
administrators across different hospitals can request each
other to register additional data (e.g. when a patient was
referred). Completeness of the NCR is estimated to be at
least 95%; missed patients are supposed to be older, receive
limited hospital care and pathological confirmation of DCC is
lacking. The study was approved by the NCR review board
and the scientific committee of the Dutch Pancreatic Cancer
Group. The need for ethical approval was waived by the
Medical Ethics Review Committee of the Amsterdam UMC,
location AMC (W18_153 #18.189). The TRIPOD statement for
reporting of prognostic studies was followed [10].
Patient selection and definitions
All patients registered to have primary invasive DCC diag-
nosed from 2009 to 2016 were included (ICD-O-3 morpho-
logical codes in Table A.1). DCC was defined as a tumor
arising below the insertion of the cystic duct and above the
ampulla of Vater (hence including mid-cholangiocarcinomas)
[1]. Both patients with pathological and nonpathologically
proven DCC were included. Patients were categorized into
resected, unresected nonmetastatic, and metastatic DCC. The
unresected nonmetastatic subgroup included both locally
advanced tumors and patients who were unfit or unwilling
to undergo surgery.
Parameters available for analysis were: year of diagnosis,
tumor morphology, age, sex, details on other cancers, socioe-
conomic status, cTNM stage, location of metastases, basis of
diagnosis (e.g. pathological confirmation), surgical explor-
ation, chemotherapy or radiotherapy (neoadjuvant, adjuvant
or palliative), survival status, time from diagnosis to death or
date of last follow-up. In the case of resected tumors, type of
resection, pTNM stage, lymph nodes harvested, number of
positive lymph nodes, differentiation grade, radicality, length
of hospital stay, 30/90-day mortality after resection. Tumor
stages were grouped based on extent of tumor growth;
tumor confined to the bile duct (T1/T2) versus invasion in
adjacent structures (T3/T4) according to the TNM 6th and 7th
edition [11,12]. Lymph node status was evaluated using both
the definition of the TNM 6/7 and the TNM 8 [11–13].
Resection margin status was classified into R0 (tumor-free
resection margins) and R1 (microscopically positive margins).
Adjuvant chemotherapy and palliative chemotherapy was
defined as administration of at least one dose. Adjuvant ther-
apy is not a standard treatment in the Netherlands and
mainly administered in clinical trials. OS was defined as time
between date of diagnosis and date of death (any cause).
Vital status of the patients was checked with the Dutch civil
municipal registry on 1 February 2018. Scores on social
deprivation derived from income, education and occupation
per 4-digit postal code area were used to assess socioeco-
nomic status (Netherlands Institute for Social Research).
Statistical analysis
Annual incidence rates adjusted to the European standard
population (ESR, version 1976) were calculated and changes
were assessed by calculating the estimated annual percent-
age of change (EAPC) and corresponding p value.
Missing data occurring in eight independent baseline vari-
ables (0.5% to 17.3%) were deemed Missing at Random
(unrelated to the outcome, possibly related to other parame-
ters) [14] and estimated using multiple imputation
(Predictive Mean Matching) with the creation of 10 datasets.
This method assumes that missing data patterns can be
modeled based on the covariates and the observed out-
comes [15].
OS was analyzed using the Kaplan–Meier method. Chi-
square test for trend (categorical data) and Mann–Whitney
U-test (continuous non-normally distributed data) were used
to assess time trends. Chi-square statistics per imputed data-
base were combined using Rubin’s rules [16]. As these rules
do not apply to nonparametric tests, logistic transformation
was applied when necessary in order to obtain a normal
distribution.
A multivariable Cox regression model (stepwise backward
selection with a p value >.10 in likelihood ratio tests for
removal) was created using known predictors of survival
from the literature [17] and factors that were of borderline
significance (p value <.10) in univariable analysis. To avoid
multicollinearity, the most relevant parameter to represent a
certain variable family were selected based on the
2Log Likelihood.
Data were analyzed using IBM SPSS Statistics for Windows
version 24.0 (IBM corp., Armonk, NY) and R version 3.4.3 (R
Foundation for Statistical Computing, Vienna, Austria, https://
www.R-project.org). A p value <.05 was considered statistic-
ally significant.
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Sensitivity analyses
Guarantee-time bias (also known as immortal bias or survivor
treatment selection bias) could possibly lead to an overesti-
mation of the effect of treatment, as a patient can only
receive a therapy if this patients survives until start of treat-
ment. In order to reduce this effect, in the first sensitivity
analysis patients who died within 90 days after resection
(resected tumors) or diagnosis (unresected tumors) were
excluded [18,19]. In the second sensitivity analysis, complete
case analyses were performed in order to evaluate the influ-
ence of methods of handling missing data. In the third
sensitivity analysis, we excluded patients without a patho-
logically confirmed diagnosis and with tumor morphology
associated with other tumors than DCC (i.e. pancreatic or
ampullary cancer) as assessed by an expert pathologist (J.V.)
(Table A.1).
Quality control
Completeness and correctness of diagnoses as registered in
the NCR were assessed for all patient undergoing resection
(as only in these cases a reliable reference standard is avail-
able) in the Amsterdam UMC, location AMC.
Results
In total, 1338 patients were registered to have DCC; 620
patients underwent resection (46.3%), 445 (33.3%) had unre-
sected nonmetastatic disease and 273 (20.4%) had metastatic
disease (Figure 1, Table 1 original data, Table A.2 imputed
data). The incidence of DCC was between 0.55 and 0.90 per
100.000 inhabitants per year in the period 2009–2016. The
incidence did not change significantly over the years (esti-
mated annual percentage of change 3.5%; p¼ .18). Of the
patients with resected, unresected nonmetastatic and meta-
static DCC, 17.3% (n¼ 107), 70.8% (n¼ 315) and 30.8%
(n¼ 84) were >75 years, respectively (p< .001). The diagnosis
of adenocarcinoma was confirmed by pathology in 85.8% of
all patients. After resection, 30-day mortality was 4.8%
(n¼ 30), 90-day mortality was 7.7% (n¼ 48) and 7.4%
(n¼ 46) received adjuvant chemotherapy. Palliative chemo-
therapy was administered in 21 (4.7%) patients with unre-
sected nonmetastatic DCC and in 78 (28.6%) with metastatic
disease. In patients with unresected nonmetastatic tumors,
134 (30.1%) died within 90 days after diagnosis, of whom
median age was 80 (IQR 74–86), 50.7% (n¼ 68/134) were
male, and only one patient received palliative chemotherapy.
In the patients with metastatic tumors, 90-day mortality was
43.2% (n¼ 118). Reasons for not starting tumor-targeted
treatment were known in a subset of patients with nonre-
sected tumors. The most frequently reported reasons were
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Figure 1. Patient flow. This figures describes the analyses as presented in the main manuscript, and the first sensitivity analysis. Two additional sensitivity analyses
(complete case analyses and pathologically proven DCC) were performed using different selections of patients.
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the patient’s performance status (35/119 documented rea-
sons) and choice of patient and/or family (32/119) in the
nonresected nonmetastatic group. This was extent of disease
(16/51), performance status (11/51) and choice of patient
and/or family (11/51) in the patients with metastatic tumors.
Over time, resection rates in patients with nonmetastatic
tumors increased from 53.6% in 2009–2012 to 61.7% in
2013–2016 (p¼ .008) and more extensive tumors (T3/T4)
were resected (p¼ .003; Table A.3). Also administration of
palliative chemotherapy in the metastatic group increased
Table 1. Characteristics and short-term outcomes of patients with distal cholangiocarcinoma in the Netherlands (2009–2016).
Total (n¼ 1338) Resected (n¼ 620) Unresected nonmetastatic (n¼ 445) Metastatic(n¼ 273)
Patient and tumor characteristics
Age 72 (64–79) 67 (60–73) 80 (74–86) 71 (63–77)
Age > 75 years 506 (37.8) 107 (17.3) 315 (70.8) 84 (30.8)
Male sex 760 (56.8) 387 (62.4) 235 (52.8) 138 (50.5)
Other cancer before diagnosis DCC (yes) 206 (15.4) 75 (12.1) 93 (20.9) 38 (13.9)
Other cancer after diagnosis DCC (yes) 48 (3.6) 30 (4.8) 14 (3.1) 4 (1.5)
Socioeconomic Status
High 385 (28.8) 183 (29.5) 128 (28.8) 74 (27.1)
Medium 533 (39.8) 266 (42.9) 164 (36.9) 103 (37.8)
Low 414 (30.9) 166 (26.7) 153 (34.4) 95 (34.8)
Unknown 6 (0.5) 5 (0.8) 0 1 (0.4)
Clinical T stage
Tis/T0/T1/T2 260 (19.4) 144 (23.2) 73 (16.4) 43 (15.8)
T3/T4 265 (19.8) 123 (19.8) 79 (12.7) 63 (23.1)
TX 730 (54.6) 346 (55.8) 233 (37.6) 151 (55.3)
Unknown 83 (6.0) 7 (1.1) 60 (13.5) 16 (5.8)
Clinical N stage
N0 785 (58.7) 484 (78.1) 203 (45.6) 98 (35.9)
N1 258 (19.3) 78 (12.6) 76 (17.1) 104 (38.1)
NX 212 (15.8) 51 (8.2) 106 (23.8) 55 (20.1)
Unknown 83 (6.0) 7 (1.1) 60 (13.5) 16 (5.8)
Location metastasesa
Liver N/A 4 (0.6) N/A 178 (63.7)
Peritoneal 1 (0.2) 59 (21.6)
Lymph node 4 (0.6) 50 (18.3)
Lung 0 45 (16.5)
Other 0 35 (12.8)
Pathology confirmation of diagnosis (yes) 1148 (85.8) 620 (100) 291 (65.4) 237 (86.8)
Pathological T stage
T0/T1/T2 N/A 158 (25.5) N/A N/A
T3/T4 451 (72.7)
TX 4 (0.6)
Unknown 7 (1.1)
Pathological N stage
N0 N/A 255 (41.1) N/A N/A
N1 348 (56.1)
NX 10 (1.6)
Unknown 7 (1.1)
Differentiation grade
Well differentiated N/A 64 (10.3) N/A N/A
Moderately differentiated 256 (41.3)
Poorly differentiated 193 (31.1)
Unknown/not determined 107 (17.3)
Radicality
No residual disease N/A 427 (68.9) N/A N/A
Microscopic residual disease 140 (22.6)
Unknown 53 (8.5)
Treatment characteristic and short term outcomes
Neoadjuvant chemotherapy (yes) N/A 3 (0.5) N/A N/A
Surgical exploration þ/ resection (yes) 707 (52.8) 620 (100) 48 (10.8) 39 (14.3)
Type of resection
Pancreatoduodenectomy N/A 603 (97.3) N/A N/A
Bile duct resection 17 (2.7)
Adjuvant chemotherapy (yes) N/A 46 (7.4) N/A N/A
Palliative chemotherapy (yes) N/A N/A 21 (4.7) 78 (28.6)
Radiotherapy, any (yes) 4 (0.6) 3 (0.6) 1 (0.4)
Length of hospital stay in daysb N/A 13 (9–21) N/A N/A
30-day mortality after resection/diagnosis N/A 30 (4.8) 65 (14.5) 39 (14.3)
90-day mortality after resection/diagnosis N/A 48 (7.7) 134 (30.1) 118 (43.2)
Original data including missing data are presented; Continuous data are presented as median with Interquartile Ranges; Categorical data are presented as counts
with percentages.
aMore than one possible.
bRegistered since 2011, missing data in 7 patients; N/A: Not Applicable.
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from 22.3% (n¼ 25) in 2009–2012 to 32.9% (n¼ 53) in
2013–2016 (p¼ .05).
Survival and prognostic factors
Median follow-up time of censored patients was 39.3 months
(IQR 24.4–62.4). Overall 1-, 3- and 5-year survival across all
stages was 46%, 18%, and 11%. Median OS was 10.4 months
(95% CI 9.5–11.4). For patients with resected, unresected
nonmetastatic and metastatic tumors, median OS was 21.9
months (95% CI 20.1–23.8), 6.7 months (95% CI 5.8–7.6) and
3.6 months (95% CI 2.9–4.4), respectively (p< .001; Table 2,
Figure 2). Survival did not significantly improve over time in
the total cohort (p¼ .55, Table A.3) or any of the subgroups.
In metastatic disease, median OS with palliative chemother-
apy was 8.2 (95% CI 6.7–9.7) versus 2.8 months (95% CI 2.
4–3.2) without (p< .001). Independent prognostic factors for
poor OS in resected disease were increasing age, T3/T4
stage, higher lymph node ratio, poor differentiation, and
R1 resection (Table 3). In metastatic tumors, administration
of palliative chemotherapy was the strongest independent
predictor of survival (HR 0.54, 95% CI 0.38–0.77, p< .001)
(Table A.4).
Quality control
Some 94 patients underwent resection in the Amsterdam
UMC, location AMC (Table A.5). After reassessment, two
patients (2.1%) were found to be incorrectly registered as
DCC by the NCR (one pancreatic cancer, one duodenal can-
cer) and three cases were incorrectly registered as non-DCC
(3.2%).
Sensitivity analyses
In resected disease, the same prognostic factors were
detected in multivariable regression analysis. For patients
with metastatic DCC surviving at least 90 days after diagnosis
(n¼ 155) OS was 9.4 months (95% CI 8.2–10.5) versus 5.2
months (4.5–5.8) with and without palliative chemotherapy
(p< .001) (Table A.6). Moreover, palliative chemotherapy was
the only independent predictor of OS (HR 0.56, 95% CI 0.
40–0.77, p< .001) (data not shown).
Table 2. Survival of patients with distal cholangiocarcinoma.
n 1-year survival 3-year survival 5-year survival Median survival, months (95% CI) p value
Total 1338 46% 18% 11% 10.4 (9.5–11.4)
Resected 620 73% 34% 22% 21.9 (20.1–23.8)
Adjuvant chemotherapy 46 83% 29% 16% 22.8 (18.8–26.9) .80
No adjuvant chemotherapy 574 72% 34% 23% 21.9 (19.9–23.8)
Unresected non-metastatic 445 30% 6% 3% 6.7 (5.8–7.6)
Palliative chemotherapy 21 38% 5% 0% 9.9 (7.9–11.9) .17
No palliative chemotherapy 424 29% 6% 3%a 6.3 (5.4–7.2)
Metastatic 273 11% 1% 0% 3.6 (2.9–4.4)
Palliative chemotherapy 78 26% 2% 0% 8.2 (6.7–9.7) <.001
No palliative chemotherapy 195 5% 0% 0% 2.8 (2.4–3.2)
Original data were used in this analysis (no missing data on described variables). Significance (p< .0001).
aMedical files of the 8 patients with unresected tumors were checked by the NCR registry administrators; in 4 patients there were doubts about the diagnosis
of DCC and/or diagnosis was revised during the clinical course.
Figure 2. Survival of patients with distal cholangiocarcinoma per stage in a nationwide cohort. Original data were used in this analysis (no missing data on
described variables); N = Number at risk; M0: nonmetastatic; M1: metastatic.
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When including only pathologically confirmed DCC no
substantial differences were seen; survival was 11.3 (95% CI
10.1–12.5), 21.5 (95% CI 19.6–23.4), 6.9 (95% CI 5.8–8.1) and
4.2 (95% CI 3.6–4.9) months for the total cohort, patients
with resected disease, unresected metastatic and metastatic
disease, respectively. Also in complete case analyses (applic-
able for time trends and regression analyses, no missing data
for other analyses), outcomes were similar (data not shown).
Discussion
In this first nationwide Western cohort of DCC, median OS
for patients with resected, unresected nonmetastatic, and
metastatic tumors was 21.9, 6.7 and 3.6 months, respectively.
Over time resection rates increased from 53.6% to 61.7%.
Adjuvant chemotherapy was rarely used, because this is not
a standard treatment in the Netherlands. Palliative chemo-
therapy was used in a minority of patients; in 4.7% of
patients with unresected nonmetastatic and 28.6% with
metastatic DCC. In the metastatic group, administration of
palliative chemotherapy increased over the years and
seemed associated with improved survival. OS, however, did
not improve significantly with time.
Our study revealed a median OS of 21.9 months for
resected DCC compared to 33 months (range 18–102) in a
2017 meta-analysis of 3258 patients including 776 Western
patients [5]. Recent large Western cohorts including about
200 [2,20,21] and 1982 [22] patients with resected DCC
revealed median OS of 18 to 39 months. Explanations for
these differences could include patient selection and varying
administration of adjuvant chemotherapy. Type of center
may also have influenced outcomes. High-volume expert
centers may treat a selected group of patients and could
benefit from a volume-outcomes relation which has previ-
ously been observed in pancreatic cancer [23,24]. The effect
of adjuvant chemotherapy could not be assessed as propor-
tional hazards assumptions were violated, only a small num-
ber of selected patients received chemotherapy and
chemotherapy strategies were unknown. Mortality rates after
pancreatoduodenectomy in our series (4.8% 30-day mortality,
7.7% 90-day mortality) were in the higher ranges as
Table 3. Predictors for overall survival in patients with resected distal cholangiocarcinoma (n¼ 620).
Univariable Cox regression analysis Multivariable Cox regression analysis
Characteristics HR 95% CI p value HR 95% CI p value
Increasing age (per year) 1.01 1.00–1.03 .005 1.02 1.01–1.03 <.001
Sex
Male 1 –
Female 1.0 0.82–1.21 .97
Year of diagnosis
2009–2012 1 –
2013–2016 1.10 0.90–1.33 .35
Socioeconomic status
Low 1 a
Medium 1.10 0.87–1.38 .42
High 0.90 0.69–1.15 .39
History of cancer
No 1 –
Yes 1.27 0.96–1.68 .10
pT stage (TNM 6/7)
T1/T2 1 1
T3/T4 1.54 1.23–1.93 <.001 1.28 1.01–1.63 .04
TX 2.49 0.74–8.45 .14 1.18 0.41–4.34 .79
pN stage (TNM 6/7)
N0 1 b
N1 2.10 1.68–2.52 <.001
NX 3.18 1.67–6.04 <.001
pN stage (TNM 8)
N0 1 b
N1 1.74 1.39–2.17 <.001
N2 2.74 2.13–3.52 <.001
NX 3.16 2.32–4.31 <.001
Lymph Node Ratio 4.80 3.29–7.01 <.001 2.85 1.87–4.33 <.001
Differentiation grade
Well differentiated 1 1
Moderately differentiated 1.22 0.85–1.76 .28 1.16 0.82–1.64 .41
Poorly differentiated 2.48 1.72–3.59 <.001 2.28 1.60–3.25 <.001
Radicality
No residual disease 1 1
Microscopic residual disease 2.01 1.68–2.57 <.001 1.81 1.45–2.26 <.001
Adjuvant chemotherapyc
No 1 –
Yes 1.05 0.74–1.45 .80
Data after multiple imputation were used; Same prognostic factors were identified when excluding patients deceasing within 90 days after resection.Significance (p< .0001).
aRemoved in backward selection.
bNot analyzed in multivariable analysis in order to avoid multicollinearity.
cProportial hazard assumption not met.
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compared to the literature. The before mentioned 2017
meta-analysis reported perioperative mortality (no definition
provided) of 4% (range 0–8%) [5]. These differences are most
likely explained by the generally worse outcomes in nationwide
data compared to high-volume export centers. This has also
been observed in a recent German nationwide study, reporting
mortality rates of 8.6% for pancreatic malignant neoplasms and
even 11.9% for nonpancreatic malignancies [25,26].
The median OS of patients with unresected nonmetastatic
disease without and with chemotherapy (6.7 and 9.9 months)
and of patients with metastatic disease without and with
chemotherapy (2.8 and 8.2 months) are not in line with
results from previous trials. The median OS of unresected bil-
iary tract cancer is typically reported between 8.1 and 12.7
months [7,27,28]. Obviously, patients selected for clinical tri-
als represent a subset of the total population with better
performance status and prognosis. For example, the current
unresected nonmetastatic group also includes patients unfit
or unwilling to undergo surgical or systemic treatment as
reflected by the median age of 80 years and a 90-day mor-
tality rate of 30%.
Our results on prognostic factors in patients undergoing
resection are in line with the two recent reviews [5,17]. A
recent propensity score matched cohort comparing adjuvant
chemotherapy with or without radiotherapy and observation
found that adjuvant therapy is only associated with
improved survival in patients with high-risk features (defined
as T3/T4 tumors, nodal positivity, lymphovascular invasion
and moderate/poor differentiation grade) [22]. These findings
highlight the importance of well-established prognostic fac-
tors. We found increased resection rates over time (53.6% vs
61.7%), which may be the result of increased awareness and
increased referrals to specialized centers with experienced
surgeons resecting more extensive tumors. To our know-
ledge, there are no previous reports on time trends in DCC,
but increased resection rates have also been observed in
pancreatic cancer [29,30].
Previous studies frequently combined intra- and extrahe-
patic cholangiocarcinomas. Although these tumors have simi-
lar morphological characteristics, there seems to be a high
intertumor genetic heterogeneity within cholangiocarcino-
mas [31,32]. Whereas intrahepatic carcinomas often harbor
IDH1/2 and FGFR mutations, extrahepatic carcinomas fre-
quently show KRAS and P53 [33,34]. In the group of resected
extrahepatic carcinomas, surgical procedures, preoperative
drainage and related complications differ for DCC and perihi-
lar cholangiocarcinoma. For patients with unresectable
tumors, current systemic treatment is equal for all cholangio-
carcinomas. However, timing and presentation of symptoms
differ, possibly leading to different outcomes. Moreover, sup-
portive care strategies, such as stenting techniques and its
complications vary; this may influence survival directly or
indirectly by delaying or cancelation of chemotherapy.
Hence, it seems more sensible to separate outcomes for dif-
ferent subtypes of cholangiocarcinoma in accordance to, for
example, the TNM classifications in which definitions for peri-
hilar carcinomas and DCC were separated since the 7th edi-
tion (2009).
The first shortcoming of this study relates to the difficulty
of establishing the diagnosis of DCC [35]. The diagnosis of
adenocarcinoma was not pathologically confirmed in 14.2%
of the cases. Besides, more than half of the cohort did not
undergo a resection, so the origin of disease (distal bile duct
versus other periampullary tumor) was determined on imag-
ing only. Moreover, we expect that nonresected tumors in
the pancreatic head in which diagnosis is unsure, are more
likely to be classified as pancreatic cancer than as DCC.
Therefore, the true total number of patients with non-
resected DCC is probably higher. Even after resection the
determination of the tumor origin may be challenging and
dependent on the pathologist’s macroscopic judgments of
the specimen. However, as long as there are no reliable bio-
markers to differentiate between these tumor types, the cur-
rent study reflects the situation in clinical practice. The
number of registration errors seemed small in the quality
control analysis and may not have had a large impact on
results. However, it should be noted that the diagnosis in
the nonresected setting is even more difficult, and results
from different diagnostic modalities and/or multidisciplinary
meetings may show conflicting results. Therefore, one can
imagine that in hindsight the patient’s medical files may be
challenging to interpret for registry administrators. It is
expected that a small number of registration errors will occur
in all countries and over all time periods. Therefore, in order
to maintain comparability with other countries and time peri-
ods, patients in whom the registered diagnosis was not DCC
in quality control were not excluded. Second, the treatment
effect may have been overestimated. It was attempted to
reduce guarantee-time bias in sensitivity analysis by exclud-
ing patients who deceased within 90 days after resection or
diagnosis. Still, treated patients mostly likely differ systemat-
ically from untreated patients (treatment selection bias). At
last, the lack of performance status which was not registered
in the NCR during this study period.
A strength of the current study is the population-based,
all-stage setting, reflecting real-life treatment and survival in
a Western country. A second strength includes the statistical
methods of handling of missing data combined with several
sensitivity analyses in order to overcome possible limitations
of registry data.
In conclusion, survival of all patients with DCC in an unse-
lected Western population-based cohort is poor and did not
improve over the time despite increased resection rates and
increased use of chemotherapy. Palliative chemotherapy is
rarely used in the unresected setting, even though this is
considered standard of care and seemed associated with
improved survival.
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